Jacky T Yeung1, Matthew D Vesely2, Danielle F Miyagishima3. 1. Department of Neurological Surgery, Yale University School of Medicine, P.O. Box 208082, New Haven, CT, 06520-8082, USA. jacky.yeung@yale.edu. 2. Department of Dermatology, Yale University School of Medicine, New Haven, CT, USA. 3. Department of Neurological Surgery, Yale University School of Medicine, P.O. Box 208082, New Haven, CT, 06520-8082, USA.
Abstract
PURPOSE: Immunotherapy has gained traction in the treatment of solid tumors but the immunological landscape of pituitary adenomas is not well defined. We sought to investigate the immunological composition in pituitary adenomas using RNA deconvolution (CIBERSORTx) on an existing gene expression dataset for pituitary adenomas. METHODS: We applied an established computational approach (CIBERSORTx) on 134 pituitary adenomas from a previously published gene expression dataset to infer the proportions of 22 subsets of immune cells. We investigated associations between each immune cell type and tumor subtype. RESULTS: We found that the majority of infiltrating immune cells within pituitary adenomas were comprised of M2 macrophages followed by resting CD4+ memory T cells and mast cells. Silent pituitary tumors have higher M2 macrophage fractions when compared to other subtypes. In contrast, Cushing pituitary tumors, both overt and subclinical cases, had higher CD8+ T cells fractions than GH tumors, prolactinomas, hyperthyroid tumors, and silent tumors. CONCLUSIONS: RNA deconvolution of the immune infiltrates of pituitary adenomas using CIBERSORTx suggests that most pituitary adenomas comprise of M2 macrophages, but each adenoma subtype has a unique immune landscape. This may have implications in targeting each adenoma subtype with different immunotherapies.
PURPOSE: Immunotherapy has gained traction in the treatment of solid tumors but the immunological landscape of pituitary adenomas is not well defined. We sought to investigate the immunological composition in pituitary adenomas using RNA deconvolution (CIBERSORTx) on an existing gene expression dataset for pituitary adenomas. METHODS: We applied an established computational approach (CIBERSORTx) on 134 pituitary adenomas from a previously published gene expression dataset to infer the proportions of 22 subsets of immune cells. We investigated associations between each immune cell type and tumor subtype. RESULTS: We found that the majority of infiltrating immune cells within pituitary adenomas were comprised of M2 macrophages followed by resting CD4+ memory T cells and mast cells. Silent pituitary tumors have higher M2 macrophage fractions when compared to other subtypes. In contrast, Cushing pituitary tumors, both overt and subclinical cases, had higher CD8+ T cells fractions than GH tumors, prolactinomas, hyperthyroid tumors, and silent tumors. CONCLUSIONS: RNA deconvolution of the immune infiltrates of pituitary adenomas using CIBERSORTx suggests that most pituitary adenomas comprise of M2 macrophages, but each adenoma subtype has a unique immune landscape. This may have implications in targeting each adenoma subtype with different immunotherapies.
Authors: Jian-Qiang Lu; Benjamin Adam; Andrew S Jack; Anna Lam; Robert W Broad; Constance L Chik Journal: Endocr Pathol Date: 2015-09 Impact factor: 3.943
Authors: Hanna R Kemeny; Aladine A Elsamadicy; S Harrison Farber; Cosette D Champion; Selena J Lorrey; Pakawat Chongsathidkiet; Karolina I Woroniecka; Xiuyu Cui; Steven H Shen; Kristen E Rhodin; Vadim Tsvankin; Jeffrey Everitt; Luis Sanchez-Perez; Patrick Healy; Roger E McLendon; Patrick J Codd; Ian F Dunn; Peter E Fecci Journal: Clin Cancer Res Date: 2019-11-19 Impact factor: 12.531
Authors: Sayka Barry; Eivind Carlsen; Pedro Marques; Craig E Stiles; Emanuela Gadaleta; Dan M Berney; Federico Roncaroli; Claude Chelala; Antonia Solomou; Maria Herincs; Francisca Caimari; Ashley B Grossman; Tatjana Crnogorac-Jurcevic; Oliver Haworth; Carles Gaston-Massuet; Márta Korbonits Journal: Oncogene Date: 2019-03-12 Impact factor: 9.867
Authors: Yu Mei; Wenya Linda Bi; Noah F Greenwald; Ziming Du; Nathalie Y R Agar; Ursula B Kaiser; Whitney W Woodmansee; David A Reardon; Gordon J Freeman; Peter E Fecci; Edward R Laws; Sandro Santagata; Gavin P Dunn; Ian F Dunn Journal: Oncotarget Date: 2016-11-22